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Chronic obstructive pulmonary disease (COPD) includes chronic bronchitis and emphysema. Environmental exposure, primarily
cigarette smoking, can cause high oxidative stress and is the main factor of COPD development. Cigarette smoke also contributes to
the imbalance of oxidant/antioxidant due to exogenous reactive oxygen species (ROS). Moreover, endogenously released ROS
during the inflammatory process and mitochondrial dysfunction may contribute to this disease progression. ROS and reactive
nitrogen species (RNS) can oxidize different biomolecules such as DNA, proteins, and lipids leading to epithelial cell injury and
death. Various detoxifying enzymes and antioxidant defense systems can be involved in ROS removal. In this review, we
summarize the main findings regarding the biological role of ROS, which may contribute to COPD development, and
cytoprotective mechanisms against this disease progression.
1. Introduction
Chronic obstructive pulmonary disease (COPD) is a major
health problem that is becoming the leading cause of morbid-
ity and mortality throughout the world [1]. This disease is
characterized by chronic inflammation, remodeling of the
small airways, and destruction of the lung parenchyma [2].
It is believed that oxidative stress is increased in patients with
COPD due to chronic exposure to cigarette smoke, a main
risk factor, which contains a high concentration of oxidants
and reactive oxygen species (ROS) (Figure 1) [3]. Other
factors can also contribute to COPD development, such as
bacterial and viral infections. Disease development is linked
to a protease/antiprotease imbalance [4] that may lead to
the lack of the protection against elastolytic enzymes. This
imbalance may also create the disproportion of oxidant/anti-
oxidant due to high endogenous ROS released by inflamma-
tory cells such as neutrophils, macrophages, and structural
cells, for example, epithelial and endothelial cells [1]. How-
ever, cells can be protected against oxidative stress by
enzymatic and nonenzymatic antioxidant systems [5]. Pre-
clinical studies and clinical trials have shown that antioxidant
molecules such as small thiol molecules (N-acetyl-L-cysteine
and carbocysteine) [6–8], antioxidant enzymes (glutathione
peroxidases) [9], activators of Nrf2-regulted antioxidant
defense system (sulforaphane) [10, 11], and vitamins, for
example, C, E, and D [12–14], can boost the endogenous
antioxidant system and reduce oxidative stress. In addition,
they may slow the progression of COPD. In this review, we
focus on the mechanism of action of endogenous and exoge-
nous ROS that can contribute to this disease development
and the cytoprotective role of antioxidant molecules [15].
2. Chronic Obstructive Pulmonary Disease
COPD is the fourth leading cause of death in the United
States [16] and is set to become the third cause of mortality
in 2020 worldwide [17]. COPD is as a common, preventable,
and treatable disease, characterized by persistent airflow lim-
itation that is usually progressive and associated with an
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enhanced chronic inflammatory response in the airways and
the lung to noxious particles or gases. The most commonly
encountered risk factor for COPD is cigarette smoke [2].
Moreover, outdoor, occupational, and indoor air pollution
may contribute to this disease development. COPD refers
mainly to two types: chronic bronchitis and emphysema.
Chronic bronchitis is defined as the presence of a cough
and sputum production for at least three months in each of
two consecutive years [16, 18]. Emphysema is characterized
by the destruction of the alveoli, the tiny air sacs in the lung
where the exchange of oxygen and carbon dioxide takes
place, which results in a decreased level of oxygen in the
blood (hypoxemia) combined with an increased level of
carbon dioxide in the blood (hypercapnia). Tuder et al.
[19, 20] indicated that cigarette smoke could induce alveolar
wall destruction by the interaction of apoptosis, oxidative
stress, and protease/antiprotease imbalance. This may cause
emphysema, which leads to the progressive and relentless
loss of lung function due to the destruction of lung paren-
chyma and chronic inflammation. Furthermore, studies from
animal models indicate that 4- to 6-month exposure to ciga-
rette smoke leads to emphysema development in mice, rats,
and rabbits [21–23]. Exacerbations of COPD are of major
global importance [24]. Exacerbations are defined as sus-
tained worsening of the patient’s condition of the stable state
and beyond normal day-to-day variations that is acute in
onset and may warrant additional treatment in a patient with
underlying COPD [25]. It has been reported that exacerba-
tions are also involved in emphysema progression in patients
with COPD [26]. Bacteria, viruses, and environmental
agents account for the vast majority of episodes of exacer-
bation. Exacerbation, systemic inflammation, ROS genera-
tion, alterations of metabolism, cardiovascular events, and
lung cancer contribute to the overall disease severity and
untimely death [2, 20].
3. Oxidative Damage of Biological Molecules
Exposure to exogenous sources of ROS such as cigarette
smoke, air pollutants, or endogenously released ROS from
leukocytes and macrophages involved in the inflammatory
process can induce oxidative stress and the oxidant/antioxi-
dant imbalance (Figure 2) [15]. Neutrophils have a key role
in inflammatory processes and have been implicated in the
development and progression of all of the pulmonary fea-
tures of COPD through the release of destructive mediators
such as neutrophil elastase and matrix metalloproteinases.
Moreover, pulmonary neutrophilic inflammation is a feature
of cigarette smoking, but importantly, in patients with
COPD, it is sustained even following smoking cessation
[27, 28]. Activated immune cells such as neutrophils and
macrophages release ROS as a part of the inflammatory pro-
cess [29]. ROS can react with biological molecules such as
lipid, protein, DNA, RNA, and mitochondrial DNA and
leads to epithelial cell injury and death (Figure 3), which con-
tribute to COPD development.
During the respiratory burst, neutrophil myeloperoxidase
catalyzes the oxidation of chloride ions (Cl−) by hydrogen per-
oxide (H2O2) to generate the anionic ROS hypochlorite (OCl-)
or its conjugate acid, hypochlorous acid (HOCl) (Figure 4(a))
[27]. The concentration of HOCl in the interstitial fluids of
inflamed tissue has been estimated to reach more than
5mM. HOCl has high reactivity, rapidly reacts with a variety
of biomolecules, and cannot reach distant intracellular targets
[30]. However, reaction of HOCl with amines can generate
much more stable chloramines that can diffuse greater dis-
tances [27]. Only a few low molecular weight amines, such
as nicotine in cigarette smoke, have been found to form chlo-
ramines that can cross cellular membranes and mediate
HOCl-induced intracellular protein damage [31].
At themolecular level, ROSmay induce lipid peroxidation
(Figure 4(b)) and yield products such as malondialdehyde,
which has the ability to inactivate many cellular proteins by
generating protein cross-linkages [32]. This may stimulate
pulmonary inflammation [33], promoting alveolar wall
destruction and emphysema development. Another product
of lipid peroxidation is 4-hydroxy-2,3-nonenal, which has
many cytotoxic effects [34]. It has been shown to cause cyto-
plasmic Ca2+ accumulation, induce expression of proinflam-
matory cytokines and NF-κB, mitochondrial dysfunction,
and apoptosis. The end products of lipid peroxidation such
as ethane, pentane, and 8-isoprostane are elevated in the
breath and serum of patients with COPD [35].
ROS can also cause reversible and irreversible protein
modifications. Protein s-sulfenation, s-nitrosylation, s-glu-
tathionylation, disulfides, thiosulfinates, sulfenamides, sulfi-
namides, and persulfides are reversible modifications [36,
37]. They are involved in redox regulation of protein func-
tions by ROS and RNS. Moreover, these modifications play
ROS in
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Figure 1: Potential contribution of ROS to various lung disease
development. ROS—reactive oxygen species; COPD—chronic
obstructive pulmonary disease; ARDS—acute respiratory distress
syndrome.
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important roles in health because they contribute to regula-
tion of cellular defense systems and protection against oxida-
tive stress. Protein carbonyls, nitrotyrosines, sulfinic acids,
sulfonic acids, and sulfonamides are irreversible modifica-
tions [37, 38]. Oxidation of proteins may lead to activation
of NF-κB, p38 MAPK, induction of inflammatory genes,
and inhibition of the activity of endogenous antiproteases,
which may contribute to this disease pathogenesis [39].
Although, irreversibly oxidized proteins are often indicators
of high oxidative stress and oxidative damage and are
detected in lung diseases, they may also be present under
normal conditions.
Moreover, ROS can also induce RNA, DNA, and mito-
chondrial DNA (mtDNA) damage. Studies suggest that RNA
is more vulnerable to oxidative damage than other cellular
components [40]. RNA could have enhanced susceptibility
for oxidative attack because of its widespread cytosolic distri-
bution, single-stranded structure, absence of protective his-
tones, and lack of an advanced repair mechanism [41]. More
than 20 different types of base damage by hydroxyl radicals
have been identified [40].
The most prevalent oxidized base in RNA is 8-
hydroxyguanosine (8-OHG). The highly reactive hydroxyl
radical first reacts with guanine to form a C8-OH adduct
radical. Then, the loss of an electron and proton generates
8-OHG (an oxidized RNA nucleoside). It is worth to
notice that RNA oxidation is more prevalent than DNA
oxidation in alveolar wall cells in emphysema [41]. How-
ever, DNA oxidation promotes microsatellite instability,
inhibits methylation, and accelerates telomere shortening.
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Figure 2: Exogenous and endogenous sources of ROS such as superoxide anions, hydrogen peroxide, hydroxyl radicals, and hypochlorous
acid in cells.
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Figure 3: ROS reaction with various biomolecules such as proteins, lipids, and DNA may cause cell injury leading to apoptosis and necrosis.
H2O2 + Cl− → OCl− + H2O
(a)
RH + •OH → H2O + R•
R• + O2 → ROO•
ROO• + RH → ROOH + R•
(b)
Q• + QH2 → 2H+ + 2Q•−
Q•− + O2 → Q + O2•−
O2•− + 2H+ → H2O2
(c)
O2•− + NO• → ONOO−
(d)
R-OO• + NO• → ROONO
(e)
Figure 4: The mechanism of ROS interaction with biomolecules. (a) Hypochlorite anion production catalyzed by myeloperoxidase; (b) lipid
peroxidation; (c) production of hydrogen peroxide; (d) peroxynitrite generation; (e) production of alkyl peroxynitrites. H2O2—hydrogen
peroxide; −OCl—hypochlorite anion; RH—unsaturated lipid; •OH—hydroxyl radical; R•—lipid radical; ROO•—lipid peroxyl radical;
ROOH—lipid peroxide; Q/QH2—quinone/hydroquinone; O2
•−—superoxide anion; NO•—nitric oxide; ONOO−—peroxynitrite;
ROONO—alkyl peroxynitrites.
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8-hydroxy-2′-deoxyguanosine (8-OHdG) is a product of
oxidized DNA and widely used as a marker of oxidative
cellular damage. Moreover, p53 mutation, observed in lung
cancer, is linked to a direct DNA damage due to exposure
to carcinogens in cigarette smoke [42]. It is worth noting
that patients with emphysema have a high risk of lung
cancer development [43]. ROS are also the main source
of mtDNA damage and mutagenesis [44]. The main prod-
ucts of mtDNA base damage are thymine glycol among
pyrimidines and 8-OHdG among purines. The former
has low mutagenicity, whereas the latter upon replication
can cause characteristic G→T transversions. MtDNA with
oxidative damage may lead to mitochondrial dysfunction
in alveolar epithelial cells [45].
4. Reactive Oxygen Species
It is believed that oxidative stress induced by cigarette smoke
and oxidative cell damage play a pivotal role in the COPD
development [7]. Cigarette smoke is a complex mixture of
numerous free radicals and ROS that can be divided into
two phases: tar (particle) and gas. Tar phase covers about
1017 relatively long-lived radical molecules per gram, for
example, quinone/hydroquinone (Q/QH2) radicals that can
reduce oxygen to produce superoxide anion (O2
•−) leading
the generation of H2O2 (Figure 4(c)) and hydroxyl radical
(•OH) [3, 46]. Primary among highly reactive ROS is •OH,
which can damage all types of macromolecules upon colli-
sion, thus having a diffusion-limited lifetime of approxi-
mately 1 nanosecond [47]. Hydroxyl radicals can be
generated by Fenton chemistry involving H2O2 and either
ferrous iron (Fe(II)) or cuprous copper (Cu(I)), which consti-
tute dangerous intersections of metal and redox homeostasis.
Particulate matter (PM) pollutants were shown to be iron-
rich and to increase oxidative stress, providing opportunity
for damaging Fenton chemistry to occur and generate •OH
in the lung [48]. Less reactive than •OH but still dangerous
is the superoxide radical anion (O2
•−), which can participate
in one electron redox chemistry, predominantly with metals
and flavin cofactors. In contrast, H2O2 is a relatively stable,
neutral ROS that can diffuse significant distances from its site
of production [47]. Unlike the superoxide radical anion,
H2O2 participates primarily in two-electron redox chemistry,
predominantly with sulfur-containing moieties in the cell.
However, H2O2 can also participate in some one-electron
chemistry with transition metals (see above for a discussion
of Fenton reaction). H2O2 can serve as a signaling molecule
at low concentrations as well as a damage agent at higher
concentrations and thus has a complex cellular role that is
defined by overlapping mechanisms of H2O2 detection, sig-
nal transduction, and destruction [49, 50]. Moreover, HOCl
generated in the presence of H2O2 can further lead to for-
mation of more toxic ROS such as •OH [27]. The high
reactivity of the hypochlorite anion (−OCl) means that it
is fairly indiscriminate in modifying its targets, typically
with second order rate constants of 105–107M−1 s−1 [51].
In proteins, cysteine, histidine, and methionine are among
the favored residues for modification. Primary amines, such
as those found in the sidechain of lysine, can also be
modified to chloramines by −OCl. In total, high ROS levels
may cause lung tissue damage and respiratory problems via
modification of diverse target molecules via distinct, ROS-
specific mechanisms.
Gas phase of cigarette smoke contains much more reac-
tive molecules than tar. This phase consists of 1015 organic
and inorganic radicals per puff [3], for example, nitric oxide
(NO•), nitrogen dioxide, and peroxynitrite (ONOO−). Ciga-
rette smoke contains 74.5–1008 ppm NO• [52] and thus rep-
resents one of the main ROS and reactive nitrogen species
(RNS) to which smokers are exposed. NO• has a short half-
life (t1/2~0.09 to 2 s) [53]; however, it reacts quickly (second
order rate constant ~2.4 ± 0.3× 106M−2 s−1) [54] with O2•−
to form peroxynitrite (ONOO−) (Figure 4(d)). Peroxynitrite
is a RNS that is involved in many physiological and patholog-
ical processes [55, 56]. Peroxynitrite possesses a very strong
oxidation and nitration capabilities, leading to damaging
molecules in cells, such as DNA and proteins. A second order
reaction depends on the concentrations of one second order
reactant or two first order reactants, which are O2
•− and
NO• in the case of peroxynitrite generation. NO• can also
react with organic lipid peroxyl radicals (ROO•) present in
cigarette smoke to form alkyl peroxynitrites (ROONO)
(Figure 4(e)), which are cytotoxic species. Moreover, NO•
and O2
•− are produced by inflammatory cells such as macro-
phages, by nitric oxide synthases (NOSs) and NADPH oxi-
dase complexes (NOXs), respectively. Furthermore, ROS
and RNS can be released by a noncontrolled process as by-
products during mitochondrial respiration, peroxisomal
metabolism [57], and protein folding maturation process in
the endoplasmic reticulum [58]. Their increased formation
leads to oxidative stress and lung damage.
5. Mitochondrial Dysfunction
Mitochondria are dynamic intracellular organelles that con-
stantly change in shape, size, number, and distribution
through constitutive cycles of fusion and fission [59]. Mito-
chondrial fusion contributes to maintain intact mitochon-
drial DNA copies, mitochondrial membrane components,
and matrix metabolites. Mitochondrial fission plays a role
in the segregation of dysfunctional mitochondria from the
pool of mitochondria. Accordingly, mitochondrial fission is
highly correlated with cell apoptosis [60]. Specifically, mito-
chondrial fission is achieved by phosphorylation of Drp1 at
Ser616, which promotes the recruitment of Drp1 from the
cytosol to the mitochondrial surface by human fission
protein-1. The possible mechanism indicates that oxidative
stress triggers mitochondrial fission and loss by enhancing
Drp1 translocation from the cytosol. Cigarette smoking-
induced mitochondrial ROS can accelerate phosphorylation
of Drp1. Therefore, prolonged oxidative stress can cause an
imbalance in fission-fusion, resulting in mitochondrial frag-
mentation, which may contribute to cell death.
Mitochondria may serve as sensors to detect perturba-
tions of intracellular homeostasis, including oxidative stress
[61]. Histone proteins are reported to protect DNA from a
variety of potentially dangerous ROS, such as •OH. High sen-
sitivity of mtDNA to damage caused by oxidative stress is
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related to the proximity to the source of ROS, the lack of
protective histones, and a relatively inefficient mtDNA
repair [62]. This may induce the synthesis of defective
mitochondrial electron transport chain subunits, further
resulting in the decreasing transmembrane potential and
leading to the abnormal overproduction of ROS, which
damage cells [59]. This further contributes to disturbances
in the redox balance leading to the imbalance between the
oxidants and antioxidants in the cell. Finally, this cause
mitochondrial dysfunction, permeabilization of the outer
mitochondrial membrane, release of apoptotic proteins, and
cell death [63]. Specifically, O2
•− can lead to mitochondrial
depolarization by facilitating cytochrome c release. Mito-
chondrial dysfunction has been reported in airway smooth
muscle cells obtained from smokers and patients with COPD
[64]. These cells were unable to provide adequate respiration
and had a severely reduced respiratory reserve capacity.
Bronchial epithelial cells obtained from ex-smokers with
COPD showed damaged mitochondria, with depletion of
cristae, increased branching, elongation, and swelling [65].
Moreover, mitochondrial dysfunction in patients with COPD
is associated with excessive mitochondrial ROS levels, which
contribute to enhanced inflammation [64].
Damaged or dysfunctional mitochondria are cleared
from the cells by the autophagy-dependent turnover of mito-
chondria (mitophagy) [66]. Mitophagy is considered a
homeostatic program that maintains a healthy mitochondrial
population for cytoprotective roles in disease pathogenesis
[67]. In contrast, mitophagy may be also a possible effector
of cell death programs. Recent studies indicate that mito-
phagy is associated with epithelial cell death in COPD, specif-
ically involving necroptosis, a form of programmed necrosis,
in response to cigarette smoke exposure. In cultured pulmo-
nary epithelial cells, cigarette smoke caused mitochondrial
dysfunction associated with a decline of mitochondrial mem-
brane potential and increased mitochondrial ROS produc-
tion. Furthermore, it was reported that mild and transient
oxidative stress induced by H2O2 does not damage mito-
chondria, but rather initiates a ROS signaling cascade, lead-
ing to the induction of selective mitophagy [68]. This in
turn would promote the selective removal of damaged mito-
chondria. Prolonged and more excessive ROS triggers early
phase of autophagic process, including cytoprotection. How-
ever, higher ROS concentrations may overload this and other
quality control systems, leading to permanent cell damage
and reduced viability. Based on these observations, ROS
can act as signaling molecules influencing cell fate. Redox
regulation can promote both survival, for example, during
starvation. On the other hand, if the prosurvival attempt fails,
high oxidative stress causes cell death [69]. Taken together,
studies suggest that mitochondrial dysfunction induced by
oxidative stress is a key contributor to the pathophysiology
of COPD. Targeting mitochondrial ROS represents a prom-
ising therapeutic approach in patients with this disease.
6. Antioxidant Defenses against ROS
Cells mount a diverse and robust defense against ROS, which
includes an overlapping array of enzyme activities that are
specific for particular ROS. Of the common ROS, only •OH
is so reactive that there are no effective enzymatic detoxifica-
tion strategies (see above for a discussion of •OH). Because
•OH is so indiscriminately destructive, no mechanisms in
the cell can effectively counter it. Although glutathione
(GSH) has been suggested as a general redox buffer against
this and other ROS, recent work suggests that GSH exerts its
antioxidant effect mostly through enzymatic pathways such
as glutaredoxins or as the reductant for glutathione peroxi-
dases [70]. Tocopherol and ascorbate form moderately stable
radicals and thus can act as “sinks” for •OH and other radicals,
although •OH will react with the first molecule it encounters,
which is unlikely to be a small molecule antioxidant.
Another radical ROS is O2
•−. The superoxide anion is
detoxified by the action of the metalloenzyme superoxide
dismutase (SOD), which converts O2
•− to H2O2 and O2
(Figure 5).
Being a dismutation, there is no net change in redox state
and thus no electrons are required for the balanced reaction
[71]. Various SODs exist and are classified according to
the metals present in their active sites, which in humans
are the Cu-Zn SODs (SOD1; intracellular, SOD3; extracel-
lular) and Mn-SOD (SOD2, mitochondrial). Notably, the
Cu-Zn and Mn-SODs have completely different three-
dimensional structures as a consequence of being members
of different fold families, suggestive of convergent evolu-
tion [72]. SODs are highly efficient enzymes, dismutating
O2
•− with a kcat/KM~7× 109M−1 s−1, which exceeds the
“diffusion limit” of ~109M−1 s−1. Enzymes operating at the
diffusion limit successfully catalyze their reaction nearly
every time they encounter substrate (i.e., they are catalytically
“perfect”), which would seem to place an upper limit on
enzyme catalytic efficiency. However, because O2
•− is an
anion, the electrostatic properties of SOD are important
and have been evolutionarily optimized to guide this nega-
tively charged substrate toward a positively charged patch
near the SOD active site. In this manner, SOD electrostati-
cally “funnels” substrate toward its active site and thus
exceeds the theoretical diffusion limit on catalytic efficiency
2O2.− O2 + H2O2
2H2O
O2 + 2H2O
SOD
2H+
2H+, 2e-
Catalase
Prx
Gpx
H2O2
2H2O2
Figure 5: Primary enzymatic means of ROS detoxification. The
relative reactivity of the ROS is indicated by color, ranging from
highly reactive (red) to inert (green). SOD—superoxide dismutases;
Prxs—peroxiredoxins; Gpxs—glutathione peroxidases.
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[73]. Therefore, SOD is remarkably proficient at removing
O2
•−, although one of its products is H2O2, another ROS.
Extracellular O2
•− produced by neutrophils is considered a
major source of alveolar and bronchial epithelial cell damage,
and the SOD system is an important component in the pul-
monary defense against hyperoxic injury [74, 75].
The predominant enzymes that handle hydrogen perox-
ide are the peroxiredoxins (Prxs), a collection of thiol-
dependent enzymes that convert peroxides into water (when
H2O2 is the substrate; Figure 5) or alcohols (when organic
peroxides of the general formula ROOH are the substrate).
Their high cellular concentration and fast rate of reaction
of Prxs with peroxides (kcat/KM~106-107M−1 s−1) mean that
they are likely the first molecules in the cell that react with
this ROS [76]. Therefore, Prxs have been postulated to be
both the front-line defense against elevated peroxide and to
mediate initial homeostatic or proliferative peroxide signal-
ing events [77]. In addition to their role in directly detoxify-
ing H2O2, the Prxs also indirectly decrease the levels of
hypochlorite (−OCl) and hydroxyl radical (•OH) by reducing
the concentration of the peroxide reactant that generates
these secondary ROS.
There are six Prxs in mammals, divided into 1-Cys or 2-
Cys classes depending on the number of critical cysteine res-
idues in their active sites. Regardless of class, all Prx reduce
peroxides via the initial formation of a cysteine sulfenic acid
(Cys-SOH) at a highly reactive, peroxidatic cysteine active
site residue. The peroxide-derived oxygen atom of the cyste-
ine sulfenic acid intermediate is released as water during the
resolution of the sulfenic acid by the attack of a second thiol,
either donated by another cysteine residue in the protein (the
resolving cysteine in the 2-Cys Prxs) or from small molecule
thiols such as glutathione (in 1-Cys Prxs). Therefore, Prx
catalysis results in disulfide-containing enzymes that must
be reduced by thioredoxin or glutaredoxin in order to restore
the resting enzyme and complete the catalytic cycle. This
process is dependent on reductases that ultimately obtain
electrons from NADPH, thereby coupling Prx-dependent
ROS detoxification to the pentose phosphate pathway, which
generates NADPH. Prxs I, II, III, and V are the isoforms that
are most highly expressed in healthy lung epithelium [78].
Additional evidence suggests that the 1-Cys Prx VI is impor-
tant specifically for the defense against lipid peroxides in the
lung [79]. A further point of particular interest is that Prx VI
also possesses phospholipase A2 activity and it is thought to
play an important role in the metabolism of lung surfactant
phospholipids that appears to be independent of its peroxi-
dase function.
Glutathione peroxidases (Gpxs) are an intriguing class of
oxidative stress defense enzymes that typically (though not
always) feature a selenocysteine residue in their active sites.
Selenocysteine, sometimes called the 21st amino acid, is
sometimes found in the active sites of redox-active enzymes
[80]. The Gpxs detoxify peroxides using a catalytic strategy
that is broadly similar to the Prxs (see above), involving the
transient oxidation of an active site residue (cysteine in the
Prxs, selenocysteine in the Gpxs) to a monooxygenated form,
either cysteine-sulfenic acid (Cys-SOH) in the Prxs or seleno-
cysteine selenenic acid (Sec-SeOH) in the Gpxs. In the Gpxs,
this Sec-SeOH is resolved by the sequential action of two
molecules of GSH. The first GSH attacks the Sec-SeOH to
form a Se-S bond with the enzyme and liberates water
(Figure 5). The second GSH regenerates the free enzyme
and produces oxidized glutathione disulfide (GSSG) with
the first GSH. As such, Gpx activity is critically linked to
the cellular glutathione pool, and the released GSSG is
reduced to GSH by NADPH-dependent glutathione reduc-
tase. Interestingly, Gpx1 deficiency results in only lung mod-
est phenotypes in mouse models; however, alteration of
pulmonary immune function has been noted [81]. In general,
it is likely that the multiple Prx and Gpx isoforms present in
mammals have significantly overlapping activities and that
redundancy has evolved in the biochemical mechanisms for
removing peroxides.
A curiosity of the cellular defense against peroxides is
that it contains so many enzymes apparently dedicated to this
task. Catalases are also hydrogen peroxide detoxifying
enzymes that, unlike the Prxs and Gpxs, use a reductase-
independent, hemedependent chemistry to convert H2O2 to
O2 (Figure 5). The hemedependent peroxidases are a related
family of enzymes that convert H2O2 to water, and some
enzymes have both activities in a single polypeptide. Cata-
lases are fast enzymes, with kcat values of ~107 s−1 but also
have very high KM values of ~1M for peroxide. Therefore,
catalases are far from their maximum rate when presented
with the nM-μM levels of H2O2 present in cells and are likely
to be kinetically outcompeted by the Prxs. This may result in
differing kinetic regimes in which the Prxs and catalases
operate, allowing effective response over a range of peroxide
insult, from chronic low level (Prxs) to acute high level stress
(catalases) [82]. Catalases are expressed in alveolar epithelial
cells and may play a particularly important role in acute
stress caused by bolus H2O2 generation, which occurs during
reoxygenation injury in the lung [83].
7. Lung Aging
The ability to prevent the oxidative damage to the lung tissue
and the potential to regenerate injured cells are two key
determinants of aging [84]. While still an area of controversy,
reports indicate that exposure to cigarette smoke, ROS, and
other environmental stressors may accelerate biological pro-
cesses associated with normal aging [85, 86]. Moreover,
recent epidemiological study has suggested that about half
of patients with COPD fail to achieve full lung function in
adolescence and early adulthood. In these individuals, this
disease might develop as a consequence of the “normal”
decline in lung function with age. Similar to emphysema,
lung aging is characterized by a decrease in the density and
an increase in the diameter of the membranous bronchioles.
However, unlike emphysema, there are no differences in
alveolar attachments. COPD may represent an accelerated
(or normal) form of lung aging.
8. Conclusions
We highlighted how environmental exposure to cigarette
smoke and endogenous ROS generated during inflammatory
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processes induce high oxidative stress, which may contribute
to COPD development. We summarized the reactivity of
the most biologically relevant ROS and RNS, which can
oxidize different biomolecules such as DNA, proteins,
and lipids. We also reviewed how oxidant molecules
(ROS) can be reduced or destroyed by diverse cytoprotec-
tive mechanisms focusing on the enzymatic protection
afforded by SODs, Prxs, Gpxs, and catalases. Antioxidant
systems, for example, GSH, vitamins A, C, and E, and
carotenoids, are important and can intersect with other
pathways [39]. Under very high oxidative stress conditions
present in patients with COPD, these mechanisms may
not correctly play their protective role, which may contribute
to exacerbation.
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